A Phase Ib Study of Ibrutinib in Combination With Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase of Trial: Phase I
Latest Information Update: 22 Dec 2017
At a glance
- Drugs Ibrutinib (Primary) ; Obinutuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 18 Dec 2017 Planned number of patients changed from 40 to 50.
- 12 Dec 2017 Results (data cut off July 5, 2017; n=24) of interim safety analysis presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 29 Jun 2016 Planned number of patients changed from 60 to 40.